MacroGenics Clinical Trials
Sponsors / MacroGenics
37 ClinicalTrials.gov entries name MacroGenics as the lead sponsor. Of these, 5 are recruiting, 1 are active without new recruitment, and 20 have completed. The registry records 9 terminated or withdrawn trials for MacroGenics. The most common reasons cited for termination include safety concerns, business or strategic decisions. Planned participant enrollment across these trials sums to 3,728. Figures on this page are sourced from ClinicalTrials.gov and refreshed with each registry update.
37
Total Trials
5
Recruiting
1
Other Active
20
Completed
9
Terminated / Withdrawn
3,728
Total Enrollment
Termination reasons: Other44% · Safety22% · Business22% · Recruitment11%
Recent Terminations
- Anal Cancer"Business reasons"
- Relapsed Acute Myeloid Leukemia"The sponsor is no longer supporting the drug"
- Advanced Solid Tumor, Adult"Business decision"
- Head and Neck Cancer"Based on internal review of safety data"
- AML"Business decision"
- Bladder Cancer"Business decision (not for safety reasons)"
- Melanoma"Unable to accrue as planned for optional biopsies"
- Acute Flaccid Paralysis"Early termination due to the inability to enroll (13 of 120 subjects enrolled)"
- Pancreatic Cancer"Corporate decision"
Active Trials (1 total)
- NCT06723236
- NCT06730347
- Advanced Cancer PHASE1NCT06242470
- NCT05362773
- Prostate Cancer PHASE2NCT06014255
- Prostate Cancer PHASE2NCT02923180